Acumen Pharmaceuticals (ABOS) Earnings

In its last earnings report on March 27, 2025, Acumen Pharmaceuticals reported earnings per share (EPS) of $-0.62, compared to an estimated EPS of $-0.47. The company reported revenue of $-, compared to an estimated revenue of $-.

Acumen Pharmaceuticals's current Price-to-Earnings (P/E) ratio is -1.01. The trailing twelve months (TTM) P/E ratio is -0.60. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.

For the fiscal year ending December 31, 2024, Acumen Pharmaceuticals reported total revenue of $- and net income of $-102.33M. This represents a net profit margin of None.

Acumen Pharmaceuticals's earnings yield is -99.13%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.

Acumen Pharmaceuticals's return on equity (ROE) is -56.28%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.

Acumen Pharmaceuticals's gross profit margin is 0.00%. This indicates that for every dollar of revenue, the company retains $0.00 as gross profit after accounting for the cost of goods sold.